AbbVie Believes Exclusive Contracts Will Deliver, Despite Disappointing Viekira Sales So Far
Executive Summary
The European launch is moving faster than expected for AbbVie’s oral HCV combination regimen, but CEO Gonzalez says U.S. sales will pick up in the second and third quarters and achieve a $3 billion run-rate during the fourth quarter.